Drug intelligence / Profile preview

CS31864

Development stage: Preclinical
Lead developer: Akeso
Modality: Small Molecules

Overview

CS31864 is a preclinical-stage small molecule inhibitor targeting the Werner syndrome ATP-dependent helicase (WRN), developed by Chipscreen Biosciences. The drug is designed to exploit the concept of synthetic lethality in cancer cells, particularly those exhibiting high microsatellite instability (MSI-H). WRN helicase is essential for the survival of MSI-H cancer cells, which are characterized by defects in DNA mismatch repair. By inhibiting WRN, CS31864 aims to induce DNA damage and cell death specifically in MSI-H solid tumors while sparing normal cells.

Targets

WRN (Werner syndrome ATP-dependent helicase)

Beyond the preview

Go deeper on CS31864.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS31864.

Explore the full profile